Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 15,175 restricted stock units to 15 newly hired non-executive officers. The awards were approved by the company's compensation committee and granted under the Ultragenyx Employment Inducement Plan on December 16, 2024. The stock units will vest over four years, with 25% vesting annually on each grant date anniversary, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has initiated patient dosing in its pivotal Phase 3 Aspire study evaluating GTX-102 for Angelman syndrome. The global study will enroll approximately 120 children aged 4-17 with genetically confirmed maternal UBE3A gene deletion. Participants will be randomized 1:1 to receive GTX-102 or sham treatment over 48 weeks.
The treatment group will receive three monthly 8mg loading doses, followed by maintenance doses up to 14mg quarterly. The study's primary endpoint focuses on cognitive improvement measured by Bayley-4 cognitive raw score, with a key secondary endpoint using the Multi-domain Responder Index across cognition, communication, behavior, motor function, and sleep. The company plans to initiate the Aurora study in 2025 to evaluate GTX-102 in other Angelman syndrome genotypes and age groups.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has submitted a Biologics License Application (BLA) to the FDA for UX111, an AAV gene therapy targeting Sanfilippo Syndrome Type A (MPS IIIA). If approved, UX111 would become the first authorized treatment in the U.S. for this condition.
The submission follows FDA's acceptance of cerebral spinal fluid (CSF) heparan sulfate (HS) as a surrogate endpoint for accelerated approval. Data from the ongoing pivotal Transpher A study showed that UX111 treatment led to rapid and sustained decreases in CSF HS levels, correlating with improved long-term cognitive development compared to natural history data. Most treatment-related adverse events were mild to moderate liver enzyme elevations that resolved.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced its participation in three major investor conferences in December 2024. The company will attend Citi's 2024 Global Healthcare Conference in Miami, the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, and Piper Sandler's 36th Annual Healthcare Conference in New York.
Key executives including CEO Emil Kakkis, CFO Howard Horn, and CMO Eric Crombez will participate in fireside chats and host one-on-one meetings across these events. Live and archived webcasts will be available on the company's investor relations website.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 20,820 restricted stock units to 13 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024. The stock units will vest over four years, with 25% of shares vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Ultragenyx Pharmaceutical (NASDAQ: RARE) presented positive Phase 1/2 data for GTX-102, its investigational treatment for Angelman syndrome, at the FAST Global Science Summit. The data supports the upcoming Phase 3 Aspire study, showing significant improvements across multiple domains at Week 48. Patients (n=40) demonstrated a mean change of +6.7 in Bayley-4 Cognition GSV score and +10.9 in Raw score. The Phase 3 study is powered at 95% to detect treatment effects. In Expansion Cohorts A&B, 80% of patients (22 of 28) achieved clinically meaningful improvement in at least one domain, with a total net response of +2.0. The Phase 3 trial will enroll 120 patients and is set to begin by year-end.
Ultragenyx Pharmaceutical (NASDAQ: RARE) reported strong Q3 2024 financial results with total revenue of $139 million, up 42% year-over-year. Crysvita revenue reached $98 million (+31% YoY), while Dojolvi revenue was $21 million (+29% YoY). The company reaffirmed its 2024 revenue guidance of $530-550 million. Despite revenue growth, Ultragenyx reported a net loss of $134 million ($1.40 per share), improved from $160 million loss in Q3 2023. The company received Breakthrough Therapy Designation for setrusumab in osteogenesis imperfecta and reported positive DTX401 Phase 3 data showing 62% mean reduction in cornstarch for GSDIa patients.
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in treatments for rare and ultrarare genetic diseases, has announced a conference call scheduled for November 5, 2024, at 5:00 p.m. ET. The call will discuss the company's third quarter 2024 financial results and provide a corporate update for the period ending September 30, 2024. The event will be accessible via webcast through the company's investor relations website, with a replay available for three months.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultrarare disease therapies, has announced the grant of 22,405 restricted stock units to six newly hired non-executive officers. The grants were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on October 16, 2024.
These stock units are designed as an employment inducement, aligning with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans four years, with 25% of the shares vesting annually on the grant date anniversary, contingent on continuous employment with Ultragenyx.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has received Breakthrough Therapy Designation from the FDA for setrusumab (UX143) to reduce fracture risk in patients 2 years and older with osteogenesis imperfecta (OI) Type I, III, or IV. This designation is based on promising clinical evidence from the Phase 2 portion of the Orbit study and the completed Phase 2b ASTEROID study, which showed a rapid and significant decrease in fracture rates.
Dr. Eric Crombez, chief medical officer at Ultragenyx, emphasized the importance of this designation in recognizing the seriousness of OI and the potential impact of setrusumab. The Breakthrough Therapy Designation aims to expedite development and review of drugs for serious diseases that show substantial improvement over existing therapies. Setrusumab has also received Orphan Drug Designation in the US and EU, rare pediatric disease designation in the US, and acceptance into the EMA's Priority Medicines program.